Autres langues Regeneron Pharmaceuticals, Inc. Sao Paulo

Actions

REGN34

BRREGNBDR005

Produits pharmaceutiques

Temps Différé 18:37:12 25/08/2026 Varia. 5j. Varia. 1 janv.
71,48 BRL +34,49% Graphique intraday de Regeneron Pharmaceuticals, Inc. +0,29% +0,89%

Autres langues

13:42 Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients
20/08 Pasatru (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial
19/08 Regeneron Announces Investor Conference Presentations
19/08 Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition
19/08 US FDA approves Regeneron's rare bone disorder drug
19/08 Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
19/08 Regeneron Pharmaceuticals Announces FDA Approval for Pasatru to Reduce Formation of New Heterotopic Ossification Lesions and Clinician-Assessed Flare-Ups in Adults with Fibrodysplasia Ossificans Progressiva
17/08 EyePoint's drug for age-related eye disease fails late-stage trial, shares tank
03/08 Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
31/07 Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says
31/07 AbbVie Lowers Outlook to Account for Acquisition, as 2Q Profit Jumps
31/07 Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on August 31, 2026
31/07 Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
30/07 Regeneron Pharmaceuticals Shares Rise After Higher Q2 Results
30/07 Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline
30/07 Afternoon Meeting: La inflación da un respiro a la Fed
30/07 The Fed Gets a Better Inflation Number
30/07 Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/07 Regeneron beats quarterly estimates on eczema drug strength, shares rise
30/07 Regeneron Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise
30/07 Regeneron Posts Higher 2Q Revenue, Sees Improving Profit
30/07 Earnings Flash (REGN) Regeneron Pharmaceuticals, Inc. Reports Q2 Revenue $4.29B, vs. FactSet Est of $3.82B
30/07 Earnings Flash (REGN) Regeneron Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $14.29 per Share, vs. FactSet Est of $10.16
30/07 Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on April 29, 2026.
30/07 Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 4, 2025.
Aucun résultat pour cette recherche